Johnson & Johnson abandons deal for Takeda’s TachoSil surgical patch

spike

The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company’s listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid

WASHINGTON (Reuters) – Johnson & Johnson (JNJ.N) said on Friday it abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, citing regulatory issues.

Takeda (4502.T), Japan’s biggest drugmaker, announced the sale of TachoSil, a surgical patch to control bleeding, to Johnson & Johnson’s subsidiary Ethicon for $400 million last May.

“Ethicon and Takeda have mutually decided to terminate

Read More